Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Show more

245 First Street, Riverview II, Cambridge, MA, 02142, United States

https://www.cyclerion.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

23.41M

52 Wk Range

$1.03 - $8.48

Previous Close

$6.38

Open

$4.94

Volume

10,959,721

Day Range

$4.65 - $6.75

Enterprise Value

20.17M

Cash

3.24M

Avg Qtr Burn

-1.579M

Insider Ownership

24.26%

Institutional Own.

7.28%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zagociguat (CY6463) Details Neurological disorder, Alzheimer's disease, Dementia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CYC-126 (Anesthetic-Based Therapy) Details Treatment-Resistant Depression	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zagociguat (CY6463) Details Cognitive Impairment Associated with Schizophrenia	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Praliciguat (sGC stimulator) Details Heart disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Olinciguat Details Sickle cell disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zagociguat (CY6463) Details Rare diseases, Mitochondrial disease, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.